irAE info

Domain Not Resolving

HSTS

DNSSEC

Font Awesome

Mobile Non Scaleable Content

nginx

US Privacy User Signal Mechanism

Cloudflare CDN

IPv6

Cloudflare

Robert Hugin

Julia Haller

Michael Casey

Carrie Cox

Michael Bonney

Jacqualyn Fouse

Richard Barker

Ernest Mario

Gerald Masoudi

Executive Vice President, General Counsel and Corporate Secretary

Keith Usiskin

Executive Director

President and Chief Operating Officer

Robert M. Hershberg

Executive Vice President, Head of Business Development and Global Alliances

Richard S. Lev

Attorney

Jerome Zeldis

CEO of Celgene Global Health

Maria Palmisano

Managing Director

Roy Paul

Associate Director

Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells.

Celularity is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies.

IDEAYA Biosciences is an oncology-focused biotechnology company that develops therapeutics for patients with genetically-defined cancers.

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.

Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. 

Agios Pharmaceuticals is a biopharmaceutical company discovers and develops therapeutics in the field of cancer metabolism.

Immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.

Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways.

United States Investors (Top 10K)

New Jersey Companies With More Than 100 Employees

Investors Active in Northeastern US (Top 10K)

East Coast Companies With More Than 100 Employees (Top 10K)

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options. 

There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma. 

In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Summit

New Jersey

United States

North America

Celgene

Bladder Cancer Market to Hit USD 6.04 Billion by 2032, at a CAGR 4.1% | VMR

BMS skates again on $6.4B Celgene shareholder lawsuit but is still not free from another filing

Bristol Myers Squibb and Celgene divulge new IKZF1 degradation inducers

Bristol Myers Squibb and Celgene discover new MK2 inhibitors

Assessment of bcma in biological samples

Compounds and compositions for selective degradation of engineered proteins

Antiproliferative compounds and methods of use thereof

Chutes & Ladders—Former Celgene CEO Alles takes the top job at TORL

Celgene discovers new PADI4 inhibitors

Methods for treating multiple myeloma

HTML5

GlobalSign

Modernizr

Google Analytics

Office 365

Wordpress

Microsoft Outlook

jQuery

Google Fonts

Vimeo

Celgene owns Signal Pharmaceuticals

Celgene owns Anthrogenesis

Celgene Corporation is a biopharmaceutical company specializing in the development and commercialization of cancer and immunology drugs. Its major product is Revlimid (lenalidomide), used in the treatment of multiple myeloma and certain anemias.

Celgene Corporation

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 9, 2024 1:46 AM	8e148209
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 9, 2024 1:46 AM	ef22e1c5
company summary	general
signals	general
crunchbase trigger	general	Nov 22, 2024 7:44 AM	a992fc59
crunchbase profile	general	Nov 22, 2024 7:47 AM	b7570f93
li profile	general
translate crunchbase fundingrounds	general	Nov 22, 2024 8:29 AM	4804d3d2
peers	general
news basic	general	Mar 9, 2024 1:46 AM	b54534ce
bundesanzeiger	filings
financials download nd	financials
private financials	financials

CELG

COM:CELGENE

Celgene Corporation